prescribed opioids and future prescription opioid misuse in teens

Given the increasingly concerning issue of prescription opioid misuse, there was a disturbing article in Pediatrics finding that even appropriate use of prescription opiates in teenagers is associated with future opioid misuse (see opioids in adolescents future misuse Peds 2015 in dropbox, or DOI: 10.1542/peds.2015-1364). details:

--prospective data from nationally representative cohorts of 6,220 12th-graders, followed up through age 23, in the Monitoring the Future study.
--initial survey data included questions on "legitimate" use of opioids, to see if the teens had ever taken narcotics because "a doctor told you to use them", as well as use of marijuana/cigarettes/non-medically prescribed opiates/barbituates/alcohol, whether they disapproved regular use of marijuana,  and some demographic and school performance questions. They also asked if in the last 12 months they had they on one or more occasions taken "narcotics other than heroin on your own -- that is, without a doctor telling you to take them", followed by a list of brand-named and generic opiate pills, as well as questions about why they were taken ("to relax or relieve tension" or "to feel good or get high")
--results:
    --legitimate opioid use by grade 12 significantly predicted future opioid misuse later (increased 33%), 69% of the teens doing so to feel good/get high, or relax/relieve tensions.
    --this association was particularly strong in those 12th graders who are "least expected to misuse opioids", including those who had disapproved or strongly disapproved of regular marijuana use and those without a history of baseline drug misuse. Teens in some of the lowest predicted risk strata for future opioid misuse (in the 1.75-3% probability) had a 3-fold increased opioid misuse if they had MD opiate prescriptions by 12th grade. Those in the 3-5% probability stratum had a doubling of opioid misuse later. There was no significant association of opioid misuse after being given legitimate opioid prescriptions in either the lowest risk group (0-1.75%) or in any of the groups with >5% risk. [for those unaware: the lowest risk stratum in this study was largely comprised of minority teens, which mirrors some other studies finding lower prevalence of opioid misuse among minority adolescents].
so, pretty impressive but observational study. clearly there are a complex array of psychosocial factors involved in opioid misuse. but this study raises the question of whether us guys giving opioids to kids increases that risk. one reasonable inference from this study is that we should minimize giving opioid prescriptions to the most absolutely needy indications and at the lowest possible dose. in many cases NSAIDs or acetaminophen will suffice (eg studies show that NSAIDs work pretty much as well as opiates for kidney stone pain, reputedly one of the most severe pains).

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more